Mendelian randomization study of serum uric acid levels and diabetes risk: evidence from the Dongfeng-Tongji cohort

Mulatibieke Keerman,¹ Fen Yang,¹ Hua Hu,¹ Jing Wang,¹ Fei Wang,¹ Zhaoyang Li,¹ Jing Yuan,¹ Ping Yao,² Xiaomin Zhang,¹ Huan Guo,¹ Handong Yang,³ Meian He ¹

To cite: Keerman M, Yang F, Hu H, *et al.* Mendelian randomization study of serum uric acid levels and diabetes risk: evidence from the Dongfeng-Tongji cohort. *BMJ Open Diab Res Care* 2020;**8**:e000834. doi:10.1136/bmjdr-2019-000834

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bmjdr-2019-000834>).

MK and FY contributed equally.

Received 16 August 2019
Revised 3 January 2020
Accepted 14 January 2020

ABSTRACT

Objective Limited Mendelian randomization (MR) studies have assessed the causal relationship between serum uric acid levels and diabetes risk. Here we investigated causality between the serum uric acid concentration and diabetes risk in Chinese population.

Research design and methods The observational analysis, based on the Dongfeng-Tongji prospective cohort (n=15 195) we tested the association of serum uric acid levels with incident diabetes risk. In the instrumental variable analysis, we examined the association of the genetic risk score (GRS) of serum uric acid with diabetes risk in case-control design (2539 cases and 4595 controls) via MR analysis.

Results During a mean (SD) follow-up of 4.5 (0.5) years, 1156 incident diabetes cases were identified. Compared with those in the lowest quintile of serum uric acid levels, the HRs of incident diabetes were 1.19 (95% CI 0.96 to 1.48), 1.12 (95% CI 0.90 to 1.40), 1.38 (95% CI 1.12 to 1.70), and 1.51 (95% CI 1.23 to 1.87) for Q2, Q3, Q4 and Q5, respectively (*P*-trend <0.001). The GRS was strongly associated with serum uric acid levels ($\beta=0.17$, 95% CI 0.15 to 0.19; $P=2.81 \times 10^{-67}$). However, no significant association was observed between the GRS and diabetes risk (OR=1.01, 95% CI 0.95 to 1.06; $P=0.75$).

Conclusions Even though serum uric acid levels were significantly associated with increased incident diabetes risk, the results did not provide evidence for a causal relationship between them.

INTRODUCTION

Type 2 diabetes (T2D) is a metabolic disorder characterized by impaired insulin sensitivity and increased insulin resistance. According to recent report, the worldwide diabetes prevalence increased from 4.3% in 1980 to 9.0% in 2014 in men, and from 5.0% to 7.9% in women, the total numbers of adults with diabetes was estimated to be 422 million in 2014.¹ The pathogenesis of T2D involves genetic factors, environmental factors, and their interaction.²

Hyperuricemia was considered to precede gout and also be associated with increased risk

Significance of this study

What is already known about this subject?

- Recent decades, a number of prospective observational studies reported positive association between serum uric acid levels and incident diabetes risk
- Limited Mendelian randomization studies assessed the causal relationship between serum uric acid levels and diabetes risk with null findings

What are the new findings?

- Whether serum uric acid levels are causally correlated with the development of diabetes?

How might these results change the focus of research or clinical practice?

- Although Mendelian randomization study did not provide evidence for causality, direct experimental investigation and large randomized controlled clinical trials are needed to determine whether lowering serum uric acid treatment can reduce the risk of diabetes.

of cardiovascular disease,³ insulin resistance,⁴ and metabolic syndrome.^{5,6} In recent decades, a number of prospective observational studies reported positive association between serum uric acid levels and incident diabetes risk,^{7–9} in contrast, some indicated negative association,¹⁰ or supported bystander role of serum uric acid levels in diabetes development.¹¹ A recent meta-analysis indicated that in the general population with each 59.48 $\mu\text{mol/L}$ uric acid concentration increase, the incident diabetes risk increased by 13%.¹² However, whether serum uric acid levels are causally correlated with the development of diabetes, is still a matter of debate.¹³ Meanwhile, serum uric acid levels were significantly associated with some potential risk factors of diabetes; therefore, it is difficult to identify the independent effects of serum uric acid on diabetes risk in observational studies.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Meian He;
hemeian@hotmail.com

Mendelian randomization study (MR) has been applied to identify the causal relationship between risk factors and outcomes.¹⁴ The main assumption of MR is, if a genetic variant is significantly associated with the risk factor, the association of a genetic variant with disease outcome can be evaluated independent of confounding factors. So far, limited MR studies assessed the causal relationship between serum uric acid levels and diabetes risk with null findings.^{15–17} In addition, most of the MR studies were conducted in European ancestry.^{15–17} Therefore, more MR studies to investigate the causal associations of serum uric acid with diabetes risk especially in different population were warranted.

In the current study, first we examined the associations of serum uric acid levels with incident diabetes risk in a prospective cohort study, furthermore, we selected 15 uric acid-associated single nucleotide polymorphisms (SNPs) that were identified in previous large-scale genome-wide association study as instrumental variable to conduct the MR analysis exploring whether there was causal relationship between serum uric acid levels and diabetes risk.

METHODS

Study populations

The Dongfeng-Tongji (DFTJ) cohort study is an ongoing prospective cohort study with 27 009 participants at baseline. Detailed baseline profiles of this study have been reported elsewhere.¹⁸ Briefly, the DFTJ cohort was launched in 2008 in the Dongfeng Motor Corporation in Shiyan city, Hubei province, China. Between 2008 and 2010, a total of 27 009 retirees were recruited and answered the questionnaires, participated in physical examination and provided fasting blood samples. Trained investigators collected information on socio-demographics,

lifestyles factors, health status and medical history via questionnaires by face-to-face interviews. During April 2013 to October 2013, the first follow-up investigation was conducted and 96.2% (25 978/27 009) of participants were successfully followed up.

For the observational analysis, individuals with self-reported stroke, ischemic heart disease, or cancer at baseline ($n=5932$) were excluded. To explore the association between serum uric acid levels and incident diabetes risk, participants with prevalent diabetes ($n=3538$) and with missing data of serum uric acid levels ($n=1742$) at baseline were also excluded. Participants with missing follow-up data were further excluded ($n=602$). Finally, leaving 15 195 participants (6655 males and 8540 females) for further observational analysis. Among the whole cohort population, genotype data were available in 7532 individuals. After exclusion of individuals with missing follow-up data ($n=127$) or with missing uric acid data ($n=271$), leaving 7134 participants (3574 males and 3560 females) for the MR analysis. Detailed study design and inclusion and exclusion criteria for the current research were summarized in figure 1

All participants provided written informed consent.

Assessment of diabetes mellitus

Diabetes were defined if one or more of the following criteria were met: (1) fasting plasma glucose (FPG) ≥ 7.0 mmol/L; (2) self-reported physician-diagnosed diabetes or currently taking anti-diabetic medication; (3) hemoglobin A_{1c} (HbA_{1c}) $\geq 6.5\%$. Cut-off value of FPG and HbA_{1c} for diagnosis of diabetes were recommended by the American Diabetes Association.¹⁹ In the present study, we did not differentiate types of diabetes.

Figure 1 Study design and study population for the current research. MR, Mendelian randomization study.

Assessment of hyperuricemia

Hyperuricemia was identified according to any of the following criteria: self-reported physician-diagnosed gout or taking anti-gout medication or males with serum uric acid levels ≥ 420 $\mu\text{mol/L}$ or females with serum uric acid levels ≥ 360 $\mu\text{mol/L}$.²⁰ According to the quintiles of gender-specific distribution, serum uric acid levels were grouped into five categories: <260 , 260–298, 299–335, 336–384 and ≥ 385 $\mu\text{mol/L}$ for males; and <202 , 202–236, 237–266, 267–308 and ≥ 309 $\mu\text{mol/L}$ for females.

Measurement of uric acid levels and other covariates

Baseline information on socio-demographics, lifestyles factors, health status, and medical history were obtained by face-to-face interviews through questionnaires. Standing height, body weight and waist circumference (WC) were measured with light indoor clothing and without shoes. Physically active was defined as having exercise regularly for at least 20 min each time in the past 6 months. Current smokers were those who smoke at least one cigarette per day and continued more than half a year. Ex-smokers were those who have quit smoking for more than half a year. Current alcohol consumers were those who drink at least one time per week and continued more than half a year. Abstainers were those who have stopped drinking for more than half a year. Prevalent hypertension was defined as blood pressure $\geq 140/90$ mm Hg, or taking anti-hypertensive medication or self-reported of physician-diagnosed hypertension. Body mass index (BMI) was calculated by weight in kilograms divided by square of height in meters. We calculated estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equation²¹. Levels of serum uric acid, creatinine and serum lipids were determined using ARCHITECT Ci8200 automatic analyzer (ABBOTT Laboratories, Abbott Park, Illinois, USA). FPG concentrations were measured with Glucose Oxidase method by Aeroset Automatic analyzer (Abbott Laboratories). HbA_{1c} levels were measured with high-performance liquid chromatography D-10 system (Bio-Rad Laboratories, Hercules, California, USA).

Genotyping and quality control

Reported SNPs were downloaded from website of Genome-Wide Association Studies (GWAS) catalog (<https://www.ebi.ac.uk/gwas/>). We searched the website of GWAS catalog for all relevant studies until March 8th, 2018 by searching for 'uric acid' or 'urate'. Finally, 72 SNPs passed the significant threshold of $<5 \times 10^{-8}$ in previous large-scale genome-wide association studies.^{22–26} Detailed information of individual SNPs was described in online supplementary table 1. We selected SNPs that passed quality control criteria, including (1) minor allele frequency (MAF) >0.05 ; (2) Hardy-Weinberg equilibrium test (P values ≥ 0.05); and (3) call rate $>95\%$. In addition, after linkage disequilibrium test and conditional analysis, we chose SNPs that passed the threshold of at least $p < 0.05$ in the present study. Detailed results of linkage

disequilibrium test were displayed in online supplementary table 2. Finally, 15 SNPs mapped in or near *PDZK1* (rs1471633), *TRIM46* (rs11264341), *SLC17A1* (rs1165151), *RFT1* (rs6770152), *NRXN2* (rs478607), *SLC2A9* (rs11722228 and rs3775948), *ABCG2* (rs2231142 and rs3114018), *LRP2* (rs2544390), *STC1* (rs17786744), *HNF4G* (rs2941484), *SLC22A12* (rs505802), *IGF1R* (rs6598541) and *BCAS3* (rs2079742) were selected for further Mendelian randomization analysis. The genotypes of the selected 15 SNPs were derived from the Affymetrix Genome-Wide Human SNP Array 6.0 Chips and Illumina Infinium OmniZhonghua-8 Chips. The genotype procedure and quality control have been described in detail in previous studies.^{27 28}

Statistical analysis

In observational analysis, we used Cox proportional hazard regression model to estimate the multivariable adjusted HRs of serum uric acid levels and hyperuricemia on incident diabetes risk. We adopted linear regression model to estimate the association of individual SNPs and the GRS with serum uric acid levels. A conditional analysis was applied with linear regression model to examine the independence of correlated SNPs. We examined the association of the GRS with potential confounders using linear regression (for quantitative variables) and logistic regression (for qualitative variables) model. Logistic regression model was also applied to calculate OR of diabetes risk for individual SNPs and the GRS with additive genetic models. Furthermore, the expected effect sizes (β_E) of individual SNPs and the GRS on diabetes risk were calculated based on the effect sizes (β_{GB}) of individual SNPs and the GRS on serum uric acid levels and the observed effect sizes (β_{BD}) of serum uric acid levels on diabetes risk: $\beta_E = \beta_{GB} \times \beta_{BD}$.²⁹ The differences between expected effect size and observed effect size were tested by students' t test.³⁰ We further conducted weighted median, inverse-variance weighted, and MR-Egger methods to estimate the causal effect of serum uric acid levels on diabetes risk.³¹ In addition, we calculated F statistic for instrumental variable selection, F statistic greater than 10 is evidence of a strong instrumental variable. Detailed information of F statistic calculation was summarized in online supplementary table 3. Statistical analyses were performed with SAS V.9.1 and R V.3.5.0 (R Project for Statistical Computing, Package: 'Mendelian Randomization').

RESULTS

In the observational analysis, a total of 15 195 individuals were included in the current study. The mean (SD) of age was 61.5 (7.6) years, and 43.8% were males. The mean (SD) of baseline serum uric acid levels were 287.18 (79.97) $\mu\text{mol/L}$ among the whole population, 304.94 (82.37) $\mu\text{mol/L}$ for those who developed incident diabetes and 285.71 (79.59) $\mu\text{mol/L}$ for those did not develop diabetes during the follow-up period. During a

mean (SD) follow-up of 4.5 (0.5) years, 1156 incident diabetes cases were identified. The incidence rate of diabetes in the present population was 7.6%, and 44.8% of them were males. Detailed baseline characteristics of the participants stratified by quintiles of baseline serum uric acid levels were summarized in [table 1](#). Individuals with higher serum uric acid concentration tended to have higher levels of BMI, WC, blood pressure, FPG, triglyceride, total cholesterol, low density lipoprotein-cholesterol, serum creatinine, and higher prevalence rate of hypertension and hyperlipidemia, in contrast, lower levels of high density lipoprotein-cholesterol (HDL-C) and eGFR. Baseline characteristics of the individuals included in the analysis and those lost to follow-up were similar (online supplementary table 4). In the MR analyses, a total of 7134 participants (2539 prevalent diabetes cases and 4595 non-diabetic controls) with genotype data were included. The mean (SD) of age was 63.4 (7.5) years and 50.1% were males. Online supplementary table 5 presented the characteristics of participants in the MR analysis.

Association of serum uric acid concentration with incident diabetes risk

In the observational analyses, compared with those in the lowest quintile of serum uric acid levels, individuals in the higher quintiles of uric acid had higher incident diabetes risk. The HRs of incident diabetes were 1.19 (95% CI 0.96, 1.48), 1.12 (95% CI 0.90, 1.40), 1.38 (95% CI 1.12, 1.70), and 1.51 (95% CI 1.23, 1.87) for individuals in Q2, Q3, Q4, and Q5, respectively (P -trend <0.001; Model 2) ([table 2](#)). The observed association attenuated but remained significant after further adjustment for baseline FPG levels (P -trend=0.003; Models 3) ([table 2](#)). When modeling as continuous variable, per SD (79.96 μ mol/L) of serum uric acid levels increase was significantly associated with 1.10 fold higher incident diabetes risk after further adjustment for potential covariates and baseline FPG levels (95% CI 1.02 to 1.17; p =0.007) ([table 2](#)).

Association of genetic variants with serum uric acid levels and diabetes risk

No significant association was observed between the GRS and potential confounders of diabetes except for smoking status (P =0.02) with marginal significance (online supplementary table 6). All selected fifteen variants were significantly and positively associated with serum uric acid concentration. The effects attenuated but remained significant after adjustment for confounders, including age, sex, BMI, smoking status, drinking status, physical activity, and eGFR (β ranged from 0.03 μ mol/L to 0.17 μ mol/L) ([table 3](#)). The individual SNPs were not associated with diabetes risk in both univariate and multivariable models ([table 3](#) and online supplementary table 7).

For the association of GRS with normal scores of uric acid levels and diabetes risk, β and OR were both obtained by per 1SD increase in genetic risk score.

In the MR analysis, we calculated GRS by summing the number of uric acid-raising alleles. The results indicated that higher GRS was strongly associated with higher serum uric acid concentration (β =0.17, 95% CI 0.15 to 0.19; P = 2.81×10^{-67}) ([table 3](#)). The GRS accounted for 2.9% of uric acid variance in the present population. No significant association was observed between the GRS and diabetes risk (OR=1.01, 95% CI 0.95 to 1.06; P =0.75) ([table 3](#)). The associations of the individual SNP or GRS with diabetes risk were not different from the expected associations based on the observed associations between these SNPs (or GRS) and serum uric acid levels and the association between uric acid levels and diabetes risk ([table 3](#)). Similarly, we did not obtain evidence for causal association of GRS and diabetes risk when three different methods (weighted median based, inverse-variance weighted, and MR-Egger) were conducted (online supplementary table 8).

DISCUSSION

Main findings

In the current large prospective cohort study we found that higher levels of serum uric acid were independently and significantly associated with an increased risk of incident diabetes. However, our findings did not support the causal role of serum uric acid levels in diabetes.

Observational analysis between serum uric acid levels and diabetes risk

Most of the previous observational studies supported positive association between serum uric acid levels and diabetes risk.^{12 32–35} Our results were in line with these findings. Moreover, in the present study the positive associations attenuated but remained significant after further adjustment for baseline fasting glucose levels, indicating the independent effects of uric acid on diabetes risk, consistent with previous study.⁹ Several potential mechanisms might account for the positive association between them. Insulin resistance is considered to be the main pathogenic mechanism underlying type 2 diabetes,³⁶ and is mediated partly by inflammation and oxidative stress.³⁷ Studies showed that serum uric acid played an important role in inducing inflammation and oxidative stress in adipocytes,^{38 39} which were closely correlated with the occurrence of type 2 diabetes.^{40 41} Moreover, experimental studies demonstrated that uric acid could directly impair insulin signaling by interfering with it at receptor level⁴² and raising uric acid with fructose could cause insulin resistance.⁴³ In addition, evidence from human intervention studies indicated that uric acid-lowering treatment could improve insulin resistance in chronic heart failure subjects with hyperuricemia⁴⁴ and decrease diabetes risk in patients with gout,⁴⁵ while other intervention study showed that urate acid-lowering agent could not improve endothelial function in type 2 diabetes cases.⁴⁶ Although numerous studies indicated that uric acid plays an important role in the development

Table 1 Baseline characteristics of participants according to quintiles of baseline serum uric acid levels (n=15 195)

Variables	Quintiles of serum uric acid concentration*					P value
	Q1	Q2	Q3	Q4	Q5	
Sample size, n	2974	3152	3009	3059	3001	–
Incident diabetes, %	5.28	6.69	6.75	8.6	10.73	<0.001
Males, %	43.98	43.18	44.03	44	43.82	0.96
Age, years	60.3 (7.4)	60.6 (7.3)	61.1 (7.4)	61.8 (7.8)	63.6 (7.8)	<0.001
Blood pressure, mm Hg						
Systolic	125 (18)	126 (18)	127 (18)	128 (18)	131 (18)	<0.001
Diastolic	77 (10)	77 (11)	78 (11)	77 (11)	78 (11)	<0.001
Waist circumference, cm	79.3 (9.1)	80.8 (8.9)	81.9 (9.3)	82.5 (9.3)	85.1 (9.6)	<0.001
BMI, kg/m ²	23.1 (3.1)	23.6 (3.1)	24.1 (3.2)	24.6 (3.2)	25.4 (3.45)	<0.001
Fasting glucose levels, mmol/L	5.41 (0.56)	5.48 (0.58)	5.51 (0.57)	5.56 (0.56)	5.65 (0.59)	<0.001
TG, mmol/L	1.11 (0.69)	1.24 (0.91)	1.30 (0.84)	1.46 (0.97)	1.70 (1.15)	<0.001
TC, mmol/L	5.01 (0.90)	5.14 (0.91)	5.14 (0.91)	5.22 (0.93)	5.29 (0.97)	<0.001
HDL-C, mmol/L	1.53 (0.42)	1.49 (0.43)	1.47 (0.38)	1.45 (0.40)	1.40 (0.41)	<0.001
LDL-C, mmol/L	2.87 (0.74)	2.99 (0.78)	3.01 (0.92)	3.06 (0.79)	3.09 (0.84)	<0.001
Serum creatinine, µmol/L	74.54 (21.85)	76.33 (17.07)	77.40 (16.65)	80.44 (27.61)	87.50 (36.81)	<0.001
Serum uric acid, µmol/L	196.36 (38.12)	245.85 (31.53)	279.98 (34.04)	317.83 (38.10)	396.55 (65.69)	<0.001
eGFR, mL min ⁻¹ (1.73 m) ⁻²	85.99 (14.71)	83.76 (14.93)	82.42 (14.22)	80.08 (30.15)	73.25 (16.46)	<0.001
Smoking status, %						<0.001
Current	20.65	18.96	20.41	18.19	17.19	
Quit	8.39	9.11	9.64	10.66	12.13	
Never	70.97	71.92	69.95	71.15	70.68	
Drinking status, %						0.92
Current	22.22	22.72	23.55	22.55	23.54	
Quit	4.14	4.35	4.1	4.22	4.43	
Never	73.64	72.93	72.35	73.23	72.02	
Physically active, %	88.67	89.59	89.73	88.82	88.8	0.54
Education levels, %						0.05
Primary or less	28.82	28.38	27.58	27.25	29.82	
High school	62.39	61.92	61.96	61.83	59.6	
College or more	8.79	9.7	10.46	10.91	10.59	
Prevalent hypertension, %	36.59	41.8	45.03	48.7	60.22	<0.001

Continued

Table 1 Continued

Variables	Quintiles of serum uric acid concentration*					P value
	Q1	Q2	Q3	Q4	Q5	
Prevalent hyperlipidemia, %	36.78	45.16	47.06	55.97	64.93	<0.001
Family history of diabetes, %	3.88	4.08	3.81	4.08	3.41	0.65

P values were calculated by one-way analysis of variance (ANOVA) for continuous variables and χ^2 test for categorical variables.

Continuous variables were described as mean (SD) and categorical variables as %.

*According to the quintiles of gender-specific distribution, serum uric acid levels were grouped into five categories: <260, 260–298, 299–335, 336–384, and ≥ 385 $\mu\text{mol/L}$ for males; <202, 202–236, 237–266, 267–308, and ≥ 309 $\mu\text{mol/L}$ for females.

BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; TC, total cholesterol; TG, triglyceride.

of diabetes,^{43 45 47} however, evidences also suggested that uric acid was also related to diabetes risk markers^{5 48 49} and uric acid might only play bystander role in diabetes risk. Therefore, whether there were causal associations between serum uric acid and diabetes risk still remained to be investigated.

Instrumental analysis between genetic variants and diabetes risk

MR analysis is a valid approach to explore causality. So far, three MR studies assessed the causal relationship between serum uric acid levels and diabetes risk with null findings.^{15–17} Among these MR studies, two studies conducted in Europeans found null causal associations of uric acid on diabetes risk with eight and 24 SNPs as instrumental variables respectively.^{15 16} Another MR study¹⁷ enrolled both Europeans and South Asians found that circulating serum urate levels were not causally correlated with cardio-metabolic diseases including T2D. However, this study was conducted using summary level data and did not control for potential mediators between genotypes and disease risk. Therefore, more MR studies to investigate the causal associations of serum uric acid with diabetes risk especially in different populations were warranted.

MR method is applied in epidemiology to test the causality of associations between risk factors and outcomes,¹⁴ which is based on the random assortment of alleles/genotypes transferred from parent to offspring at the time of gamete formation. The results of MR study are based on the following assumptions. First, single genetic variants and/or instrumental variables (GRS) should be associated with risk factor of interest. In the present study, all SNPs we selected were strongly associated with serum uric acid concentrations in large-scale genome-wide association studies^{22–26} and also validated in the present population. In addition, all SNPs we selected were not in linkage disequilibrium with each other and conditional analysis indicated these SNPs were independently associated with serum uric acid levels. Second, genetic variants should be independent of potential confounders. No significant associations were observed between the GRS and potential confounders, except for smoking status with marginally significance. When we additionally adjusted for smoking status in instrumental variable estimates on diabetes risk, the null-effect remained (online supplementary table 7). Finally, single genetic variants and/or instrumental variables (GRS) should affect the outcomes only through the risk factor of interest. This assumption depends on background knowledge of the underlying biology. Most of the SNPs we selected are mapped in or near genes responsible for cellular transport of uric acid, which suggests that these SNPs might directly influence serum uric acid levels. However, one previous phenome-wide association study found that missense SNP rs2231142 in *ABCG2* gene was also correlated with blood pressure levels and protoporphyrin levels,⁵⁰ suggesting pleiotropy. Besides, the initial reports on *SLC2A9* described

Table 2 Incident rates and hazard ratios of diabetes according to quintiles of baseline serum uric acid levels and hyperuricemia status (n=15 195)

	Participants (cases)	Person years	Incidence rate per 1000 Person years	HR (95% CI)		
				Model 1*	Model 2†	Model 3‡
Quintiles of uric acid§	15 195 (1156)	68 486.40	16.9	–	–	–
Q1	2974 (157)	13 508.80	11.6	Ref.	Ref.	Ref.
Q2	3152 (211)	14 252.80	14.8	1.18 (0.96 to 1.46)	1.19 (0.96 to 1.48)	1.06 (0.85 to 1.32)
Q3	3009 (203)	13 588.50	14.9	1.15 (0.93 to 1.42)	1.12 (0.90 to 1.40)	1.04 (0.84 to 1.30)
Q4	3059 (263)	13 759.90	19.1	1.41 (1.15 to 1.72)	1.38 (1.12 to 1.70)	1.26 (1.02 to 1.56)
Q5	3001 (322)	13 376.40	24.1	1.58 (1.30 to 1.92)	1.51 (1.23 to 1.87)	1.25 (1.01 to 1.55)
P-trend	–	–	–	<0.001	<0.001	0.003
Uric acid (1 SD)	–	–	–	1.17 (1.10 to 1.24)	1.15 (1.07 to 1.22)	1.10 (1.02 to 1.17)
P value	–	–	–	<0.001	<0.001	0.007
Non-hyperuricemia	–	–	–	Ref.	Ref.	Ref.
Hyperuricemia	–	–	–	1.46 (1.23 to 1.72)	1.38 (1.15 to 1.64)	1.26 (1.06 to 1.51)
P value	–	–	–	<0.001	<0.001	0.009

P trend was calculated using the median value of each quintile to construct an ordinal variable.

SD=79.96 µmol/L uric acid.

*Results from multivariable model adjusted for age, sex and body mass index.

†Results from multivariable model adjusted for all variables in model 1 plus smoking status, drinking status, education level, physical activity, prevalent hypertension, prevalent hyperlipidemia, estimated glomerular filtration rate, and family history of diabetes.

‡Results from multivariable model adjusted for all variables in model 2 plus baseline fasting plasma glucose levels.

§According to the quintiles of gender-specific distribution, serum uric acid levels were grouped into five categories: <260, 260–298, 299–335, 336–384, and ≥385 µmol/L for males; <202, 202–236, 237–266, 267–308, and ≥309 µmol/L for females.

Table 3 Association of individual SNPs and the genetic risk score with serum uric acid levels and diabetes risk (n=7134)

SNP-risk allele	Gene	Effect size on uric acid levels		Observed association with diabetes risk		Expected association with diabetes risk		Observed association with diabetes risk adjusted for uric acid	
		β (95% CI)*	P value	OR (95% CI)†	P value	OR (95% CI)	P value‡	OR (95% CI)	P value
rs1471633-A	PDZK1	0.05(0.01 to 0.08)	1.73×10^{-2}	0.95 (0.86 to 1.05)	0.35	1.005 (1.005 to 1.005)	0.31	0.95 (0.86 to 1.05)	0.34
rs11264341-C	TRIM46	0.07 (0.04 to 0.11)	1.78×10^{-5}	1.01 (0.92 to 1.10)	0.82	1.008 (1.008 to 1.008)	0.96	1.01 (0.92 to 1.10)	0.86
rs1165151-G	SLC17A1	0.09 (0.05 to 0.13)	1.38×10^{-6}	1.03 (0.94 to 1.13)	0.53	1.009 (1.009 to 1.009)	0.67	1.03 (0.93 to 1.13)	0.58
rs6770152-G	SERBP1P3	0.04 (0.01 to 0.06)	1.33×10^{-2}	1.02 (0.95 to 1.10)	0.52	1.004 (1.004 to 1.004)	0.59	1.02 (0.95 to 1.10)	0.54
rs478607-G	NRXN2	0.06 (0.02 to 0.10)	1.11×10^{-3}	0.99 (0.91 to 1.09)	0.89	1.006 (1.006 to 1.006)	0.79	0.99 (0.91 to 1.09)	0.86
rs11722228-T	SLC2A9	0.14 (0.11 to 0.17)	6.53×10^{-20}	0.97 (0.89 to 1.06)	0.52	1.015 (1.015 to 1.015)	0.31	0.97 (0.89 to 1.05)	0.45
rs3775948-C	SLC2A9	0.17 (0.14 to 0.19)	8.11×10^{-30}	1.00 (0.93 to 1.08)	0.92	1.017 (1.017 to 1.017)	0.65	1.00 (0.92 to 1.07)	0.89
rs2231142-T	ABCG2	0.16 (0.13 to 0.19)	1.14×10^{-25}	1.04 (0.93 to 1.13)	0.32	1.017 (1.017 to 1.017)	0.56	1.04 (0.96 to 1.12)	0.39
rs3114018-C	ABCG2	0.12 (0.09 to 0.15)	3.07×10^{-15}	1.02 (0.94 to 1.10)	0.64	1.012 (1.012 to 1.012)	0.88	1.01 (0.94 to 1.10)	0.72
rs2544390-T	LRP2	0.05 (0.02 to 0.08)	1.00×10^{-3}	1.04 (0.96 to 1.12)	0.3	1.005 (1.005 to 1.005)	0.37	1.04 (0.96 to 1.12)	0.33
rs17786744-G	STC1	0.03 (0.01 to 0.06)	2.77×10^{-2}	1.00 (0.92 to 1.08)	0.98	1.003 (1.003 to 1.003)	0.91	1.00 (0.92 to 1.08)	0.95
rs2941484-T	HNF4G	0.04 (0.01 to 0.07)	7.88×10^{-3}	0.97 (0.90 to 1.05)	0.54	1.004 (1.004 to 1.004)	0.48	0.97 (0.90 to 1.05)	0.52
rs505802-C	SLC22A12	0.05 (0.02 to 0.09)	1.69×10^{-3}	0.98 (0.90 to 1.08)	0.75	1.006 (1.005 to 1.005)	0.66	0.98 (0.90 to 1.07)	0.73
rs6598541-A	IGF1R	0.03 (0.01 to 0.06)	2.11×10^{-2}	1.05 (0.97 to 1.13)	0.22	1.003 (1.003 to 1.003)	0.26	1.05 (0.97 to 1.13)	0.23
rs2079742-T	BCAS3	0.03 (0.01 to 0.06)	2.44×10^{-2}	0.95 (0.88 to 1.02)	0.17	1.003 (1.003 to 1.003)	0.14	0.95 (0.88 to 1.02)	0.15
GRS		0.17 (0.15 to 0.19)	2.81×10^{-67}	1.01 (0.95 to 1.06)	0.75	1.018 (1.018 to 1.018)	0.72	1.01 (0.96 to 1.06)	0.75

*Estimates from linear regression (additive genetic model) on serum uric acid levels ranks per one risk allele increase, adjusted for age, sex, body mass index, smoking status, drinking status, physical activity, and estimated glomerular filtration rate. Computed normal scores of uric acid levels from the ranks were used to calculate β estimates.

†Estimates from logistic regression model (additive genetic model) on diabetes risk per one risk allele increase, adjusted for age, sex, body mass index, smoking status, drinking status, physical activity, education levels, estimated glomerular filtration rate, hypertension, hyperlipidemia and family history of diabetes.

‡P value for difference between expected and observed association with diabetes risk.

GRS, genetic risk score.

a fructose and glucose transport activity,^{51 52} indicating pleiotropy nature of *SLC2A9* gene. However, when we additionally excluded these potential pleiotropy SNPs in *ABCG2* and *SLC2A9* from instrumental analysis, the null-effect still remained (online supplementary table 9). Additionally, we used the MR-Egger regression methods to test the potential pleiotropy nature of SNPs.³¹ The intercept term estimated from MR-Egger regression was centered at the origin with a CI including the null, suggesting that our results were not being influenced by pleiotropy. In the current study, no significant association was observed between the genetic score and diabetes risk (OR=1.01, 95 CI 0.95 to 1.06; p=0.75), which was in line with the results of previous MR studies.^{15–17} In addition, when we estimated the association between the genetic score and diabetes risk based on the previous reported SNPs that independently associated with serum uric acid levels in Chinese population²⁴, the null-effect still remained (online supplementary table 10). This might be due to the relatively small sample size in MR analysis, the limited SNPs included and the relative minor effects of SNPs on uric acid levels.

Strengths and limitations

Strengths of the current study included its large sample size, prospective design, and standardized measurements of diabetes risk factors. Both in observational analysis and instrumental analysis, we took a wide spectrum of known or potential confounders of diabetes risk into consideration, including socio-demographics, lifestyles factors, and biochemical factors. In addition, we used multiple uncorrelated SNPs associated with serum uric acid levels to calculate GRS, which increased the precision of the estimate. However, there are several potential limitations that could be considered in the current study. First, in line with previous MR studies,^{15 16} in the current study the GRS only explained 2.9% of serum uric acid variation. Finding more uric acid susceptibility loci was warranted to investigate the causal associations in future studies. Second, our analyses were confined to middle-aged and elderly Chinese population, which limits generalizability to other ancestries or the young population. Finally, we cannot exclude the possibility of residual confounding, although we took possible risk factors of diabetes into consideration.

In conclusion, even though serum uric acid levels were significantly associated with increased incident diabetes risk, the results from Mendelian randomization study did not provide evidence for a causal relationship between serum uric acid levels and diabetes risk.

Author affiliations

¹Department of Occupational and Environmental Health and State Key Laboratory of Environmental and Health (incubating), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

²Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

³Department of Cardiovascular Disease, Dongfeng Motor Corporation General Hospital, Shiyan, China

Acknowledgements The authors thank the staff and the participants of the Dongfeng-Tongji (DFTJ) cohort study for their contributions.

Contributors MK, FY and MH took part in the study design and data collection. MH supervised the study. MK, FY and MH drafted the manuscript. All authors critically revised the manuscript for important intellectual content and approved the version to be published. All authors had access to the data, commented on the report drafts and approved the final submitted version.

Funding The grants from the National Key R&D Program of China (2017YFC0907501 and 2016YFC0900800), the Program for HUST Academic Frontier Youth Team (2017QYTD18), and the National Natural Science Foundation (grant NSFC-81522040 and 81473051).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The Medical Ethics Committee of the School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China and the Ethics Committee of Dongfeng General Hospital, Shiyan, China.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Meian He <http://orcid.org/0000-0002-2096-921X>

REFERENCES

- 1 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016;387:1513–30.
- 2 Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *The Lancet* 2014;383:1068–83.
- 3 Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. *Heart* 2013;99:759–66.
- 4 Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. *Diabetes* 2013;62:3307–15.
- 5 McKeigue PM, Campbell H, Wild S, et al. Bayesian methods for instrumental variable analysis with genetic instruments ('Mendelian randomization'): example with urate transporter SLC2A9 as an instrumental variable for effect of urate levels on metabolic syndrome. *Int J Epidemiol* 2010;39:907–18.
- 6 Dai X, Yuan J, Yao P, et al. Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population. *Eur J Epidemiol* 2013;28:669–76.
- 7 Dehghan A, van Hoek M, Sijbrands EJJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. *Diabetes Care* 2008;31:361–2.
- 8 Bhole V, Choi JWW, Kim SW, et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. *Am J Med* 2010;123:957–61.
- 9 Juraschek SP, McAdams-Demarco M, Miller ER, et al. Temporal relationship between uric acid concentration and risk of diabetes in a community-based study population. *Am J Epidemiol* 2014;179:684–91.
- 10 Taniguchi Y, Hayashi T, Tsumura K, et al. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka health survey. *J Hypertens* 2001;19:1209–15.
- 11 Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? *Metabolism* 2006;55:1293–301.
- 12 Xu Y-L, Xu K-F, Bai J-L, et al. Elevation of serum uric acid and incidence of type 2 diabetes: A systematic review and meta-analysis. *Chronic Dis Transl Med* 2016;2:81–91.
- 13 Johnson RJ, Merriman T, Lanasa MA. Causal or Noncausal relationship of uric acid with diabetes: table 1. *Diabetes* 2015;64:2720–2.

- 14 Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014;23:R89–98.
- 15 Pfister R, Barnes D, Luben R, *et al.* No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. *Diabetologia* 2011;54:2561–9.
- 16 Sluijs I, Holmes MV, van der Schouw YT, *et al.* A Mendelian randomization study of circulating uric acid and type 2 diabetes. *Diabetes* 2015;64:3028–36.
- 17 Keenan T, Zhao W, Rasheed A, *et al.* Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. *J Am Coll Cardiol* 2016;67:407–16.
- 18 Wang F, Zhu J, Yao P, *et al.* Cohort profile: the Dongfeng–Tongji cohort study of retired workers. *Int J Epidemiol* 2013;42:731–40.
- 19 American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2012;35:S64–71.
- 20 Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National health and nutrition examination survey 2007–2008. *Arthritis & Rheumatism* 2011;63:3136–41.
- 21 Levey AS, Stevens LA, Schmid CH, *et al.* A new equation to estimate glomerular filtration rate. *Ann Intern Med* 2009;150:604–12.
- 22 Köttgen A, Albrecht E, Teumer A, *et al.* Genome-Wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet* 2013;45:145–54.
- 23 Kamatani Y, Matsuda K, Okada Y, *et al.* Genome-Wide association study of hematological and biochemical traits in a Japanese population. *Nat Genet* 2010;42:210–5.
- 24 Yang B, Mo Z, Wu C, *et al.* A genome-wide association study identifies common variants influencing serum uric acid concentrations in a Chinese population. *BMC Med Genomics* 2014;7:10.
- 25 Okada Y, Sim X, Go MJ, *et al.* Meta-Analysis identifies multiple loci associated with kidney function-related traits in East Asian populations. *Nat Genet* 2012;44:904–9.
- 26 Kolz M, Johnson T, Sanna S, *et al.* Meta-Analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. *PLoS Genet* 2009;5:e1000504.
- 27 He M, Wu C, Xu J, *et al.* A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. *Gut* 2014;63:143–51.
- 28 He M, Xu M, Zhang B, *et al.* Meta-Analysis of genome-wide association studies of adult height in East Asians identifies 17 novel loci. *Hum Mol Genet* 2015;24:1791–800.
- 29 Li S, Zhao JH, Luan J, *et al.* Genetic predisposition to obesity leads to increased risk of type 2 diabetes. *Diabetologia* 2011;54:776–82.
- 30 Freathy RM, Timpson NJ, Lawlor DA, *et al.* Common variation in the FTO gene alters diabetes-related metabolic traits to the extent expected given its effect on BMI. *Diabetes* 2008;57:1419–26.
- 31 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512–25.
- 32 Kodama S, Saito K, Yachi Y, *et al.* Association between serum uric acid and development of type 2 diabetes. *Diabetes Care* 2009;32:1737–42.
- 33 Lv Q, Meng X-F, He F-F, *et al.* High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. *PLoS One* 2013;8:e56864.
- 34 Jia Z, Zhang X, Kang S, *et al.* Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. *Diabetes Res Clin Pract* 2013;101:88–96.
- 35 Bellou V, Belbasis L, Tzoulaki I, *et al.* Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. *PLoS One* 2018;13:e0194127.
- 36 DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care* 1991;14:173–94.
- 37 Furukawa S, Fujita T, Shimabukuro M, *et al.* Increased oxidative stress in obesity and its impact on metabolic syndrome. *J. Clin. Invest.* 2004;114:1752–61.
- 38 Sautin YY, Nakagawa T, Zharikov S, *et al.* Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *Am J Physiol Cell Physiol* 2007;293:C584–96.
- 39 Zhou Y, Fang L, Jiang L, *et al.* Uric acid induces renal inflammation via activating tubular NF- κ B signaling pathway. *PLoS One* 2012;7:e39738.
- 40 Duncan BB, Schmidt MI, Pankow JS, *et al.* Low-Grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis risk in Communities study. *Diabetes* 2003;52:1799–805.
- 41 Kaneto H, Katakami N, Kawamori D, *et al.* Involvement of oxidative stress in the pathogenesis of diabetes. *Antioxid Redox Signal* 2007;9:355–66.
- 42 Tassone EJ, Cimellaro A, Perticone M, *et al.* Uric acid impairs insulin signaling by promoting ENPP1 binding to insulin receptor in human umbilical vein endothelial cells. *Front Endocrinol* 2018;9:98.
- 43 Nakagawa T, Hu H, Zharikov S, *et al.* A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* 2006;290:F625–31.
- 44 Ogino K, Kato M, Furuse Y, *et al.* Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. *Circ Heart Fail* 2010;3:73–81.
- 45 Niu S-W, Chang K-T, Ta A, *et al.* Decreased incidence of diabetes in patients with gout using benzbromarone. *Rheumatology* 2018;57:1574–82.
- 46 Waring WS, McKnight JA, Webb DJ, *et al.* Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. *Diabetologia* 2007;50:2572–9.
- 47 Li X, Meng X, Gao X, *et al.* Elevated serum xanthine oxidase activity is associated with the development of type 2 diabetes: a prospective cohort study. *Diabetes Care* 2018;41:dc171434–890.
- 48 Oikonen M, Wendelin-Saarenhovi M, Lyytikäinen L-P, *et al.* Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. the cardiovascular risk in young Finns study. *Atherosclerosis* 2012;223:497–503.
- 49 Palmer TM, Nordestgaard BG, Benn M, *et al.* Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. *BMJ* 2013;347:f4262.
- 50 Hall MA, Verma A, Brown-Gentry KD, *et al.* Detection of pleiotropy through a Phenome-wide association study (PheWAS) of epidemiologic data as part of the environmental architecture for genes linked to environment (Eagle) study. *PLoS Genet* 2014;10:e1004678.
- 51 Augustin R, Carayannopoulos MO, Dowd LO, *et al.* Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. *Mol Membr Biol* 2004;279:16229–36.
- 52 Manolescu AR, Augustin R, Moley K, *et al.* A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity. *Mol Membr Biol* 2007;24:455–63.